UCB (OTCMKTS:UCBJY) Reaches New 1-Year Low – Should You Sell?

UCB SA (OTCMKTS:UCBJY) hit a new 52-week low during trading on Tuesday. The stock traded as low as $111.47 and last traded at $111.5325, with a volume of 12,542 shares traded. The stock had previously closed at $113.96.

Wall Street Analyst Weigh In

A number of brokerages recently commented on UCBJY. Zacks Research lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 16th. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

UCB Trading Down 3.0%

The firm has a fifty day moving average of $122.64 and a 200 day moving average of $136.53.

About UCB

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.